

Product Data Sheet

Product Name: Senexin C

Cat. No.: GC73100

Chemical Properties

Cas. No. 2375554-02-0


Formula $C_{28}H_{27}N_5O$ M.Wt 449.55

Solubility DMSO : 33.33 mg/mL (74.14 mM; ultrasonic and warming and heat to 160°C) Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability.

Senexin C (compound 20a) exhibits potent CDK8/19 inhibitory activity with high selectivity (IC₅₀s of 56 and 108 nM for 293-NFκB-Luc and MV4-11-Luc cells, respectively)[1]. Senexin C (2 μM) shows

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

potency in different kinase assays (IC₅₀= 3.6 nM for CD8/CycC, K_d=1.4 nM for CD8/CycC, K_d=2.9 nM for CDK19/CycC)[1]. Senexin C (1 μM, 3 h) shows inhibition on CDK8/19 dependent cellular gene expression[1].

Senexin C (2.5 mg/kg, i.v.; 100 mg/kg, p.o.) shows good oral bioavailability[1]. Senexin C (40 mg/kg; p.o.; twice daily for 4 weeks) suppresses the systemic growth of MV4-11 AML with good tolerability[1]. Pharmacokinetic Parameters of Senexin C in eight-week-old female Balb/c mice[1].

References:

[1]. Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65(4):3420-3433.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA